✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹9,012 Cr.
P/E
74.24
About
Ami Organics Limited is a R&D driven manufacturer specializing in advanced pharmaceutical intermediates for APIs and NCEs, along with key starting materials for agrochemicals and fine chemicals. The c… Read more
Ami Organics Limited is a R&D driven manufacturer specializing in advanced pharmaceutical inte… Read more
Low
1008
52W Range
High
2644
  • AMI Organics
  • Supriya Lifescience
  • Aether Industries
  • TJI Pharma - API & CRAMS

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

7 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Market Share
50 %
(as of Mar 21)
4-Dihydroxy 5 Nitrobenzaldehyde - Market Share
40 %
(as of Mar 21)
6-Methoxy Carbonyl-2-Oxindole-Fg Market Share
88 %
(as of Mar 21)
Dichloropyrimidine Market Share
60 %
(as of Mar 21)
Glycidyl Phthalimide Market Share
75 %
(as of Mar 21)
Intermediate - Amino Acetaldehyde Dimethyl Acetal - Global Market Share
45 %
(as of Mar 21)
Morpholin-3-One Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Verticals

Therapeutic Area Break-Up

Acute vs Chronic

Asset Break-Up - Segment Wise

API Break-Up

Peer Comparison
Corporate Actions
Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less
FAQs on AMI Organics Ltd. Business

Ami Organics Limited specializes in advanced pharmaceutical intermediates and key starting material for agrochemical and fine chemicals. They are a major manufacturer for key APIs like Dolutegravir and Rivaroxaban.

AMI Organics major competitors are Supriya Lifescience, Aether Industries, Shilpa Medicare, Aarti Pharmalabs, Granules India, Alivus Life Sciences, Aarti Drugs.
Market Cap of AMI Organics is ₹9,012 Crs.
While the median market cap of its peers are ₹6,679 Crs.

AMI Organics seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Sep
Investor Presentation Mar May Jun Sep Dec Mar Jun Sep Dec Feb Mar May Jun Aug Sep Dec Sep Dec
Conference Call Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Sep Dec
Conference Call SummaryCon Call Summary
Discussions & Analysis
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material